Drug Approval | January 08, 2026
Briefs: Medicamen Biotech and Gland Pharma
Gland Pharma receives approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
Gland Pharma receives approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
Cidara will become a wholly owned subsidiary of Merck and the common stock of Cidara will no longer be listed or traded on the Nasdaq Global Market
The SNS records neural activity from 60 channels across four brain regions—far exceeding current commercial devices
CystoSmart, an AI tool designed to detect bladder tumors during screening and surveillance cystoscopy, is brand-agnostic and works with flexible, rigid, and single-use scopes
Valneva said regaining full rights to the vaccine will allow the company to “assume direct control over its supply chain and commercialization for endemic high-risk countries
Syrma Johari is a globally recognised medical device engineering and manufacturing organisation
The portfolio, purchased from a leading multinational generic manufacturer, addresses a market valued at $473.2 million for the 12 months ending August 2025
The study met its primary endpoint with flying colors
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
Subscribe To Our Newsletter & Stay Updated
